REFERENCES
2. Bailey DB Jr, Gehtland LM, Lewis MA, et al. Early check: translational science at the intersection of public health and newborn screening. BMC Pediatr 2019;19:238.
3. Loeber JG, Burgard P, Cornel MC, et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1. From blood spot to screening result. J Inherit Metab Dis 2012;35:603-11.
4. Chan K, Brower A, Williams MS. Population-based screening of newborns: Findings from the newborn screening expansion study (part two). Front Genet 2022;13:867354.
5. Kemper AR, Green NS, Calonge N, et al. Decision-making process for conditions nominated to the recommended uniform screening panel: statement of the US Department of Health and Human Services Secretary’s Advisory Committee on heritable disorders in newborns and children. Genet Med 2014;16:183-7.
6. Brower A, Chan K, Williams M, et al. Population-based screening of newborns: findings from the NBS expansion study (part one). Front Genet 2022;13:867337.
8. Jones SA, Cheillan D, Chakrapani A, et al. Application of a novel algorithm for expanding newborn screening for inherited metabolic disorders across Europe. Int J Neonatal Screen 2022;8:20.
9. Loeber JG, Platis D, Zetterström RH, et al. Neonatal screening in Europe revisited: an ISNS perspective on the current state and developments since 2010. Int J Neonatal Screen 2021;7:15.
10. Scarpa M, Bonham JR, Dionisi-Vici C, et al. Newborn screening as a fully integrated system to stimulate equity in neonatal screening in Europe. Lancet Reg Health Eur 2022;13:100311.
11. Wilson JMG, Jungner G. principles and practice of screening for disease. Geneva; 1968. Available from: https://niercheck.nl/wp-content/uploads/2019/06/Wilson-Jungner-1968.pdf [Last accessed on 13 Sep 2023]
12. Andermann A, Blancquaert I, Beauchamp S, Déry V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ 2008;86:317-9.
13. Jansen ME, Metternick-Jones SC, Lister KJ. International differences in the evaluation of conditions for newborn bloodspot screening: a review of scientific literature and policy documents. Eur J Hum Genet 2016;25:10-6.
14. Sikonja J, Groselj U, Scarpa M, et al. Towards achieving equity and innovation in newborn screening across Europe. Int J Neonatal Screen 2022;8:31.
15. Botkin JR, Clayton EW, Fost NC, et al. Newborn screening technology: proceed with caution. Pediatrics 2006;117:1793-9.
16. Friedman JM, Cornel MC, Goldenberg AJ, Lister KJ, Sénécal K, Vears DF. Global Alliance for Genomics and Health Regulatory and Ethics Working Group Paediatric Task Team. Genomic newborn screening: public health policy considerations and recommendations. BMC Med Genomics 2017;10:9.
17. Howard HC, Knoppers BM, Cornel MC, Wright Clayton E, Sénécal K, Borry P. European Society of Human Genetics; P3G International Paediatric Platform; Human Genome Organisation; and the PHG Foundation. Whole-genome sequencing in newborn screening? A statement on the continued importance of targeted approaches in newborn screening programmes. Eur J Hum Genet 2015;23:1593-600.
18. Johnston J, Lantos JD, Goldenberg A, Chen F, Parens E, Koenig BA. members of the NSIGHT Ethics and Policy Advisory Board. Sequencing newborns: a call for nuanced use of genomic technologies. Hastings Cent Rep 2018;48 Suppl 2:S2-6.
19. Knoppers BM, Sénécal K, Borry P, Avard D. Whole-genome sequencing in newborn screening programs. Sci Transl Med 2014;6:229cm2.
20. Potter BK, Avard D, Entwistle V, et al. Ethical, legal, and social issues in health technology assessment for prenatal/preconceptional and newborn screening: a workshop report. Public Health Genomics 2009;12:4-10.
21. Castilla I, Arvelo-Martín A, Valcárcel-Nazco C, et al. Cost-effectiveness of the expanded newborn screening of congenital errors of metabolism using tandem mass spectrometry. Available from: https://sescs.es/coste-efectividad-cribado-de-errores-congenitos-del-metabolismo-mediante-espectrometria-de-masas/ [Last accessed on 13 Sep 2023]
22. Ramos-Goñi JM, Serrano-Aguilar PG, Espada Sáenz-Torres M, Posada de la Paz M. Coste-efectividad del cribado neonatal de los errores congénitos del metabolismo mediante espectrometría de masas en tándem. Madrid; 2008. Report No.: Servicio de Evaluación del Servicio Canario de la Salud. SESCS; 2006. Available from: https://sescs.es/coste-efectividad-del-cribado-neonatal-por-espectrometria-de-masas-en-tandem/ [Last accessed on 13 Sep 2023]
23. Castiñeras DE, Couce ML, Marin JL, González-Lamuño D, Rocha H. Newborn screening for metabolic disorders in Spain and worldwide. An Pediatr 2019;91:128.e1-14.
24. Chan K, Petros M. Simple test, complex system: multifaceted views of newborn screening science, technology, and policy. Glob Pediatr Health 2019;6:2333794X19894812.
25. Hoffmann GF, Lindner M, Loeber JG. 50 years of newborn screening. J Inherit Metab Dis 2014;37:163-4.
26. Serrano-aguilar P, Castilla-rodríguez I, Vallejo-torres L, Valcárcel-nazco C, García-pérez L. Neonatal screening in Spain and cost-effectiveness. Expert Opinion on Orphan Drugs 2015;3:971-4.
27. Cacciatore P, Visser LA, Buyukkaramikli N, van der Ploeg CPB, van den Akker-van Marle ME. The methodological quality and challenges in conducting economic evaluations of newborn screening: a scoping review. Int J Neonatal Screen 2020;6:94.
28. Garavito GA, Moniz T, Déom N, Redin F, Pichini A, Vindrola-Padros C. The implementation of large-scale genomic screening or diagnostic programmes: A rapid evidence review. Eur J Hum Genet 2023;31:282-95.
29. Pollitt RJ, Green A, Mccabe CJ, et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome: a review. Health Technol Asses 1997:1.
30. Baily MA, Murray TH. Ethics, evidence, and cost in newborn screening. Hastings Cent Rep 2008;38:23-31.
31. Chan K, Davis J, Pai SY, Bonilla FA, Puck JM, Apkon M. A markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID). Mol Genet Metab 2011;104:383-9.
32. Gaspar HB, Hammarström L, Mahlaoui N, Borte M, Borte S. The case for mandatory newborn screening for severe combined immunodeficiency (SCID). J Clin Immunol 2014;34:393-7.
33. Johnson K, Lloyd-Puryear MA, Mann MY, Ramos LR, Therrell BL. Financing state newborn screening programs: sources and uses of funds. Pediatrics 2006;117:S270-9.
35. Simon D, Broadbridge E, Baker M, et al. Common challenges and identified solutions for state newborn screening programs during COVID-19 pandemic. Int J Neonatal Screen 2022;8:7.
36. Ley 14/1986, de 25 de abril, General de Sanidad. Available from: https://www.boe.es/eli/es/l/1986/04/25/14/con [Last accessed on 9 Sep 2023].
37. Royal Decree 1030/2006, of September 15, which establishes the portfolio of common services of the National Health System and the procedure for updating it. Available from: https://www.boe.es/eli/es/rd/2006/09/15/1030/con [Last accessed on 13 Sep 2023].
38. Couce ML, Castiñeiras DE, Bóveda MD, et al. Evaluation and long-term follow-up of infants with inborn errors of metabolism identified in an expanded screening programme. Mol Genet Metab 2011;104:470-5.
39. The Spanish Network of Agencies for Health Technology Assessment and Services of the National Health System (RedETS); 2023. Available from: https://redets.sanidad.gob.es/ [Last accessed on 9 Sep 2023].
40. Royal Decree-Law 16/2012, of April 20, on urgent measures to guarantee the sustainability of the National Health System and improve the quality and safety of its benefits; 2012. Available from: https://www.boe.es/eli/es/rdl/2012/04/20/16/con [Last accessed on 9 Sep 2023].
41. Sobrido Prieto M, González Guitián C, Cerdá Mota T, group of technicians and experts in documentation, and diffusion/dissemination belonging to the Spanish Health Technology Assessment Agencies & Units. Strategies for the diffusion and dissemination of health technology assessment (HTA) products. Madrid: Ministry of Science & Innovation; 2010. Available from: https://redets.sanidad.gob.es/productos/buscarProductos.do?metodo=descargarFichero&idProducto=135 [Last accessed on 9 Sep 2023].
42. Langer A, Holle R, John J. Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening. BMC Health Serv Res 2012;12:300.
43. Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ 2018;27:746-61.
44. Valcárcel-Nazco C, García-Pérez L, Linertová R, et al. Cost-effectiveness methods of newborn screening assessment. Rev Esp Salud Publica 2021;95:e202101009. Available from: https://www.mscbs.gob.es/biblioPublic/publicaciones/recursos_propios/resp/revista_cdrom/VOL95/C_ESPECIALES/RS95C_202101009.pdf [Last accessed on 9 Sep 2023]
45. Grosse SD, Thompson JD, Ding Y, Glass M. The use of economic evaluation to inform newborn screening policy decisions: the washington state experience. Milbank Q 2016;94:366-91.
46. Forman J, Coyle F, Levy-Fisch J, Roberts P, Terry S, Legge M. Screening criteria: the need to deal with new developments and ethical issues in newborn metabolic screening. J Community Genet 2013;4:59-67.
47. Nicholls SG, Southern KW. Informed choice for newborn blood spot screening in the United Kingdom: a survey of parental perceptions. Pediatrics 2012;130:e1527-33.
48. Wright SJ, Ulph F, Dharni N, Payne K. Eliciting preferences for information provision in newborn bloodspot screening programs. Value Health 2017;20:651-61.
49. Bailey DB Jr, Gehtland L. Newborn screening: evolving challenges in an era of rapid discovery. JAMA 2015;313:1511-2.
50. Wasserstein MP, Andriola M, Arnold G, et al. Clinical outcomes of children with abnormal newborn screening results for Krabbe disease in New York State. Genet Med 2016;18:1235-43.
51. Howson CP, Cedergren B, Giugliani R, et al. Universal newborn screening: a roadmap for action. Mol Genet Metab 2018;124:177-83.
53. Fischer KE, Grosse SD, Rogowski WH. The role of health technology assessment in coverage decisions on newborn screening. Int J Technol Assess Health Care 2011;27:313-21.
54. Fischer KE, Rogowski WH. Funding decisions for newborn screening: a comparative review of 22 decision processes in Europe. Int J Environ Res Public Health 2014;11:5403-30.
55. Cameron D, Ubels J, Norström F. On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. Glob Health Action 2018;11:1447828.
56. Eichler HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-28.
57. Marsh KD, Sculpher M, Caro JJ, Tervonen T. The use of MCDA in HTA: great potential, but more effort needed. Value Health 2018;21:394-7.
58. Boy N, Mengler K, Thimm E, et al. Newborn screening: a disease-changing intervention for glutaric aciduria type 1. Ann Neurol 2018;83:970-9.
59. Gramer G, Fang-Hoffmann J, Feyh P, et al. Newborn screening for vitamin B12 deficiency in Germany-strategies, results, and public health implications. J Pediatr 2020;216:165-72.e4.
60. Mütze U, Garbade SF, Gramer G, et al. Long-term outcomes of individuals with metabolic diseases identified through newborn screening. Pediatrics 2020;146:e20200444.
61. Hall K. 12th ISNS European regional meeting oral and poster abstracts. Int J Neonatal Screen 2021;7:71.
